NEW BRUNSWICK, N.J., Oct. 20 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US: SNT) announced today that Catherine Taylor, one of the Company's funded researchers, will be presenting her findings related to Senesco's preclinical multiple myeloma data at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics." Ms. Taylor is a member of the Department of Biology at the University of Waterloo, Ontario, Canada. The conference will take place from October 21-24 in Geneva, Switzerland.
Senesco's President and CEO, Bruce Galton, Executive Vice President and CSO, Dr. John E. Thompson, and Vice President of R&D, Richard Dondero, are all co-authors of the study entitled "Therapeutic intervention in a murine model of multiple myeloma with PEI nanocomplexes bearing an eIF5A siRNA and eIF5AK50R pDNA resulted in a significant anti-tumoural response."
A copy of the poster will be available at http://www.senesco.com once the presentation has been made.
About Senesco Technologies, Inc.
Senesco Technologies, Inc. is a U.S. biotechnology company,
headquartered in New Brunswick, NJ. Senesco has initiated preclinical
research to trigger or delay cell death in mammals (apoptosis) to determine
if the technology is applicable in human medicine. Accelerating apoptosis
may have applications to development of cancer treatments. Delaying
apoptosis may have applications to certain diseases inflammatory and
ischemic diseases. Senesco takes its name from the scientific term for the
aging of plant cells: senescence. Delaying cell breakdown in plants extends
freshness after harvesting, while increasing crop yields, plant size and
resistance to environmental stress. The Company believes that its
technology can be used to develop superior strains of crops without any
modification other than delaying natural plant senescence. Senesco has
|SOURCE Senesco Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved